Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
”Press release: Phase III REZILIENT3 trial meets its primary endpoint.
Adding zipalertinib to first line chemotherapy for advanced NSCLC with an EGFR exon 20 insertion mutation significantly improved PFS over chemo alone.”
Other articles about lung cancer on OncoDaily.